Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance

Abstract

Aim: Resistance to chemotherapy is a major limiting factor that hamper the effectiveness of anticancer therapies. Doxorubicin is an antineoplastic agent used in the treatment of a wide range of cancers. However, it presents several limitations such as dose-dependent cardiotoxicity, lack of selectivity for tumor cells, and induced cell resistance. Nanotechnology represents a promising strategy to avoid these drawbacks. In this work, new albumin-based nanoparticles were formulated for the intracellular delivery of doxorubicin with the aim to overcome cancer drug resistance.

Methods: Glycol chitosan-coated and uncoated albumin nanoparticles were prepared with a tuned coacervation method. The nanoformulations were in vitro characterized evaluating the physicochemical parameters, morphology, and in vitro release kinetics. Biological assays were performed on A2780res and EMT6 cells from human ovarian carcinoma and mouse mammary cell lines resistant for doxorubicin, respectively.

Results: Cell viability assays showed that nanoparticles have higher cytotoxicity than the free drug. Moreover, at low concentrations, both doxorubicin-loaded nanoparticles inhibited the cell colony formation in a greater extent than drug solution. In addition, the cell uptake of the different formulations was investigated by confocal microscopy and by the HPLC determination of doxorubicin intracellular accumulation. The nanoparticles were rapidly internalized in greater extent compared to the free drug.

Conclusion: Based on these results, doxorubicin-loaded albumin nanoparticles might represent a novel platform to overcome the mechanism of drug resistance in cancer cell lines and improve the drug efficacy.

Keywords

Albumin / nanoparticles / doxorubicin / glycol chitosan / drug resistance / ovarian and breast cancer

References

[1] Genovese I,Assaraf YG,Colotti G.Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins..Drug Resist Updat2017;32:23-46

[2] Vasan N,Hyman DM.A view on drug resistance in cancer..Nature2019;575:299-309

[3] Kyrochristos ID,Roukos DH.Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy..Drug Discov Today2019;24:1281-94

[4] Zhitnyak IY,Sukhorukova IV.Effect of BN Nanoparticles Loaded with Doxorubicin on Tumor Cells with Multiple Drug Resistance..ACS Appl Mater Interfaces2017;9:32498-508

[5] Markman JL,Holler E.Nanomedicine therapeutic approaches to overcome cancer drug resistance..Adv Drug Deliv Rev2013;65:1866-79 PMCID:PMC5812459

[6] Bar-Zeev M,Assaraf YG.Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance..Drug Resist Updat2017;31:15-30

[7] Majidinia M,Rahimi M.Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons..IUBMB Life2020;72:855-71

[8] Lepeltier E,Rizzolio F.Nanomedicine to target multidrug resistant tumors..Drug Resist Updat2020;52:100704

[9] Kesharwani SS,Tummala H.Overcoming multiple drug resistance in cancer using polymeric micelles..Expert Opin Drug Deliv2018;15:1127-42

[10] Lee ES.Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation..J Phar Investig2016;46:305-15

[11] Bhushan B,Khlebtsov B,Gopinath P.Impact of albumin based approaches in nanomedicine: Imaging, targeting and drug delivery..Adv Colloid Interface Sci2017;246:13-39

[12] Kimura K,Nishi K.Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique..Cancer Chemother Pharmacol2019;83:1113-20

[13] Onafuye H,Mulac D,Wass MN.Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells..Beilstein J Nanotechnol2019;10:1707-15 PMCID:PMC6720578

[14] Kayani Z,Bordbar AK.Doughnut-shaped bovine serum albumin nanoparticles loaded with doxorubicin for overcoming multidrug-resistant in cancer cells..Int J Biol Macromol2018;107:1835-43

[15] Chen B,Zhuo RX.A self-assembled albumin based multiple drug delivery nanosystem to overcome multidrug resistance..RSC Adv2015;5:6807-14

[16] England CG,Kuttan A,Frieboes HB.Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles..Eur J Pharm Biopharm2015;92:120-9 PMCID:PMC4430429

[17] Beretta GL.Engineering nanomedicines to overcome multidrug resistance in cancer therapy..Curr Med Chem2016;23:3-22

[18] Kunjachan S,Möckel D.Overcoming cellular multidrug resistance using classical nanomedicine formulations..Eur J Pharm Sci2012;45:421-8

[19] Salomon JJ.Nanoparticles attenuate P-glycoprotein/MDR1 function in A549 human alveolar epithelial cells..Eur J Pharm Biopharm2011;77:392-7

[20] El-Awady RA,Al-Tunaiji H.Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy..Cancer Biol Ther2015;16:1056-70 PMCID:PMC4622527

[21] Mohajeri M.Protective effects of curcumin against doxorubicin-induced toxicity and resistance: a review..Crit Rev Oncol Hematol2018;122:30-51

[22] Rivankar S.An overview of doxorubicin formulations in cancer therapy..J Cancer Res Ther2014;10:853-8

[23] Caldera F,Trotta F.Cyclic nigerosyl-1,6-nigerose-based nanosponges: An innovative pH and time-controlled nanocarrier for improving cancer treatment..Carbohydr Polym2018;194:111-21

[24] Daga M,Argenziano M.GSH-targeted nanosponges increase doxorubicin-induced toxicity “in vitro” and “in vivo” in cancer cells with high antioxidant defenses..Free Radic Biol Med2016;97:24-37

[25] Argenziano M,Clemente N.Improvement in the anti-tumor efficacy of Doxorubicin nanosponges in in vitro and in mice bearing breast tumor models..Cancers (Basel)2020;12:162 PMCID:PMC7016577

[26] Zhao N,Mixson AJ.Advances in delivery systems for doxorubicin..J Nanomed Nanotechnol2018;9:519 PMCID:PMC6319900

[27] Gonçalves M,Rodrigues J.A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market..J Control Release2020;317:347-74

[28] Duan J,Zhang Y.Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles..Int J Pharm2012;426:193-201

[29] Misra R,Sahoo BS.Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation..Int J Pharm2014;475:372-84

[30] Zhao M,Yang Y.Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp..PLoS One2015;10:e0131429 PMCID:PMC4504487

[31] Vallo S,Michaelis M.Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells..Oncol Lett2017;13:4085-92 PMCID:PMC5453046

[32] An FF.Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery..Theranostics2017;7:3667-89 PMCID:PMC5667340

[33] Baboci L,Di Cintio F.The dual role of the liver in nanomedicine as an actor in the elimination of nanostructures or a therapeutic target..J Oncol2020;2020:4638192 PMCID:PMC7060440

[34] Gabizon A,Barenholz Y.Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies..Clin Pharmacokinet2003;42:419-36

[35] Pieper S,Mulac D.Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity..Beilstein J Nanotechnol2019;10:2062-72 PMCID:PMC6839550